 |
|
|
| |
Long-Acting MK-8591 at IAS 2019, , New ART for Treatment, PrEP
|
| |
| |
Download the PDF
MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing
EFdA / MK-8591 - HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection - (08/05/16)
MK-8591 (4=-Ethynyl-2-Fluoro-2=Deoxyadenosine) Exhibits Potent Activityagainst HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture
MK-8591 (4=-ethynyl-2-fluoro-2=-deoxyadenosine [EFdA]) (Fig. 1) is an investigational nucleoside analog that inhibits HIV-1 replication with 50% effective concentrations (EC50s) in the low nanomolar-to-picomolar range (12–16). Direct comparisons show that MK-8591 is 10-fold more potent than tenofovir disoproxil fumarate (TDF) (15), 10 to100 times more potent than zidovudine (AZT) (12, 14), and 1,000 times more potent than emtricitabine (FTC) (16) against HIV-1 in culture.
IAS: ISLATRAVIR (ISL, MK-8591) at doses of 0.25 to 2.25 mg QD in combination with doravirine maintains viral suppression through 48 weeks in adults with HIV-1 infection - (07/26/19)
IAS: First-in-Human Trial of MK-8591-Eluting Implants Demonstrates Concentrations Suitable for HIV Prophylaxis for at Least One Year - (07/25/19)
IAS: Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection - (07/25/19)
IAS 2019 - 45 reports so far
IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention
Mexico City
July 21-24 2019
|
| |
|
|
|
|
|
